Liver transplantation for metastatic non-resectable gastrointestinal stromal tumor after molecular targeted therapies: A case report

Hui Li; Xiaole Meng; Kun Zhang; Huamei Tang

doi:10.1016/j.ijscr.2022.107185

Liver transplantation for metastatic non-resectable gastrointestinal stromal tumor after molecular targeted therapies: A case report

Int J Surg Case Rep. 2022 Jun:95:107185. doi: 10.1016/j.ijscr.2022.107185. Epub 2022 May 11.

Authors

Hui Li¹, Xiaole Meng², Kun Zhang³, Huamei Tang⁴

Affiliations

¹ Department of Pathology, Xiang'an Hospital of Xiamen University, Xiamen 361000, China.
² Department of Pathology, Xiang'an Hospital of Xiamen University, Xiamen 361000, China; National Institute for Data Science in Health and Medicine, Xiamen University, Xiamen 361000, China; Organ Transplantation Institute of Xiamen University, Fujian Provincial Key Laboratory of Organ and Tissue Regeneration, School of Medicine, Xiamen University, Xiamen 361000, China.
³ Organ Transplantation Institute of Xiamen University, Fujian Provincial Key Laboratory of Organ and Tissue Regeneration, School of Medicine, Xiamen University, Xiamen 361000, China; Organ Transplantation Surgery Department, Xiang'an Hospital of Xiamen University, Xiamen 361000, China. Electronic address: kzhang@xah.xmu.edu.cn.
⁴ Department of Pathology, Xiang'an Hospital of Xiamen University, Xiamen 361000, China; Organ Transplantation Institute of Xiamen University, Fujian Provincial Key Laboratory of Organ and Tissue Regeneration, School of Medicine, Xiamen University, Xiamen 361000, China. Electronic address: tanghuamei2014@163.com.

Abstract

Introduction and importance: Metastatic GIST (gastrointestinal stromal tumor) is most commonly seen in the liver. Surgical resection and Imatinib administration are the preferred treatment for localized and potentially resectable GIST. However, it is still a matter of debate about the optimal therapeutic management for unresectable, liver-confined, metastatic GIST even after the administration of imatinib. The present case illustrates the possibility of LT surgery maybe for unresectable GIST.

Case presentation: A 56-year-old man revealed clinical symptoms such as abdominal pain, eating little, fullness of abdomen, and fatigue. A 6.0 cm tumor in the fundus of the stomach was found by gastroscopy, which was confirmed to be GIST by pathological biopsy and molecular testing. Abdominal enhanced CT scanning showed multiple hepatic mass occupying synchronous. Then the patient initiated on targeted drug therapy of Imatinib (400 mg daily). A year later, a follow-up abdominal enhanced CT scanning showed that no tumor was found in the gastric fundus except the thickened gastric wall with poor dilatation, and the liver tumors were significantly smaller than before. When the patient showed symptoms of drug resistance, he was refered to our hospital for LT. The surgery was very successful, and the patient is disease-free and there is no evidence of recurrence until the paper was finished.

Discussion and conclusion: Metastatic GIST to the whole liver is a rare clinical entity requiring unique considerations for treatment. Treatment based on LT might be the last resort therapy for unresectable, liver-confined, metastatic GIST in transplant oncology.

Keywords: Case report; GIST; Liver transplantation; Metastatic; Unresectable.